Moving the Needle 2023 - Panel Three - CA CURE Elicio Therapeutics, Inc.
HTML-код
- Опубликовано: 1 окт 2024
- Robert Connelly, CEO of Elicio Therapeutics, Inc. discusses their project funded by the CA CURE initiative of the GI Research Foundation: Development of a Lymph Node Targeting Vaccine for Patients with BRAF V600E and TP53 R248W Tumor Neoantigens